Histone Deacetylase Inhibitors and Epigenetic Modifications as a Novel Strategy in Renal Cell Carcinoma

類似資料

• Histone modifications: implications in renal cell carcinoma
  著者:: Ramakrishnan, Swathi, 等
  出版事項: (2013)
• Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies
  著者:: Ellis, Leigh, 等
  出版事項: (2010)
• Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
  著者:: Li Shen, 等
  出版事項: (2012-01-01)
• Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
  著者:: Shen, Li, 等
  出版事項: (2012)
• Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma
  著者:: Wood, Anthony, 等
  出版事項: (2019)